Drugs & Targets FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC February 27, 2026Vol.52 No.08
A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risksRespirators (restricted by federal regulation) may or may not be the answer February 20, 2026Vol.52 No.07By Sara Willa Ernst
News Analysis NIH Director Bhattacharya named acting CDC director in latest public health shakeupThe temporary appointment concentrates vast authority in the hands of one person February 20, 2026Vol.52 No.07By Claire Marie Porter
Guest Editorial California Institute of Regenerative Medicine and Cancer Research: A promise broken? February 20, 2026Vol.52 No.07By Stephen J. Forman
Sponsored Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform February 20, 2026Vol.52 No.07By Christine Brown and Enrique Montero
Cancer Policy At Friends meeting, Pazdur, Woodcock lament FDA’s failure to protect the agency staff from political interference, warn of “lasting implications” February 20, 2026Vol.52 No.07By Jacquelyn Cobb and Claire Marie Porter
Cancer Policy Bayer agrees to $7.25B settlement over lawsuits alleging Roundup weedkiller caused cancer February 20, 2026Vol.52 No.07By Sara Willa Ernst
In Brief James Downing to step down as president and CEO of St. Jude to focus on global pediatric medicine February 20, 2026Vol.52 No.07
In Brief Alice Soragni joins CU Anschutz to launch functional personalized medicine initiative February 20, 2026Vol.52 No.07
